| Mar'19 | Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | |
|---|---|---|---|---|---|---|
Revenue: | ||||||
Total revenues | ||||||
0 | 0 | 0 | 0 | 0 | 0 | |
Operating expenses: | ||||||
Research and development | ||||||
2,296 | 993 | 1,034 | 1,028 | 824 | 383 | |
General and administrative | ||||||
2,180 | 915 | 516 | 511 | 495 | 202 | |
Total operating expenses | ||||||
4,476 | 1,908 | 1,551 | 1,539 | 1,319 | 586 | |
Loss from operations | ||||||
-4,476 | -1,908 | -1,551 | -1,539 | -1,319 | -586 | |
Interest income | ||||||
23 | 88 | 0 | 0 | - | - | |
Net loss | ||||||
-4,452 | -1,820 | -1,551 | -1,539 | -1,319 | -586 | |
Other comprehensive loss: | ||||||
Foreign currency translation adjustment | ||||||
-299 | 564 | -760 | 135 | 28 | 16 | |
Comprehensive loss | ||||||
-4,752 | -1,255 | -2,312 | -1,403 | -1,291 | -570 | |
Net loss per share, basic and diluted | ||||||
-0.02 | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | |
Weighted average number of common shares outstanding | ||||||
180,903 | 150,070 | 205,000 | 201,726 | 200,000 | 185,315 | |